IU
IUI1.F Intuitive Surgical Inc
- Market cap
- EUR 138B
- P/E
- 55.9x
- P/B
- 9.67x
- ROE
- 18.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IUI1.F undervalued?
Graham numberThe Graham number of Intuitive Surgical Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Intuitive Surgical Inc fundamental analysis
No fundamental analysis for Intuitive Surgical Inc yet.
Intuitive Surgical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Intuitive Surgical Inc
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasi…
Full company profileIntuitive Surgical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Intuitive Surgical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.70B | 3.13B | 3.72B | 4.48B | 4.36B | 5.71B | 6.22B | 7.12B | 8.35B | 10.1B | 11.6B |
| Gross Profit | 1.89B | 2.19B | 2.60B | 3.11B | 2.86B | 3.96B | 4.20B | 4.73B | 5.63B | 6.64B | 7.83B |
| Operating Income | 945M | 1.05B | 1.20B | 1.37B | 1.05B | 1.82B | 1.58B | 1.77B | 2.35B | 2.95B | 3.83B |
| EBITDA | - | 1.15B | 1.32B | 1.58B | 1.33B | - | 1.94B | 2.22B | 2.85B | 3.62B | 4.69B |
| Net Income | 736M | 660M | 1.13B | 1.38B | 1.06B | 1.70B | 1.32B | 1.80B | 2.32B | 2.86B | 2.88B |
| EPS | - | 5.88 | 9.85 | 12 | 9.01 | 4.77 | 3.78 | 5.10 | 6.51 | 8.04 | 8.16 |
| Balance Sheet | |||||||||||
| Total Assets | 6.49B | 5.76B | 7.85B | 9.73B | 11.2B | 13.6B | 13.0B | 15.4B | 18.7B | 20.5B | 19.3B |
| Total Liabilities | 709M | 1.03B | 1.16B | 1.45B | 1.41B | 1.60B | 1.86B | 2.04B | 2.21B | 2.52B | 3.23B |
| Shareholders' Equity | 5.78B | 4.73B | 6.68B | 8.26B | 9.76B | 12.0B | 11.1B | 13.3B | 16.4B | 17.8B | 16.0B |
| Cash & Short-term Investments | 1.04B | 648M | 858M | 1.17B | 1.62B | 1.29B | 1.58B | 2.75B | 2.03B | 3.37B | 2.98B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.09B | 1.14B | 1.17B | 1.60B | 1.48B | 2.09B | 1.49B | 1.81B | 2.42B | 3.03B | 4.26B |
| Capital Expenditure | 53.9M | 191M | 187M | 426M | 342M | 340M | 532M | 1.06B | 1.11B | 540M | 439M |
| Free Cash Flow | - | 953M | 982M | 1.17B | 1.14B | 1.74B | 958M | 750M | 1.30B | 2.49B | 3.82B |
| Ratios | |||||||||||
| ROE | 12.7% | 14.0% | 16.9% | 16.7% | 10.9% | 14.3% | 11.9% | 13.5% | 14.1% | 16.0% | 18.0% |
| ROA | 11.3% | 11.5% | 14.4% | 14.2% | 9.5% | 12.6% | 10.2% | 11.6% | 12.4% | 14.0% | 14.9% |
| Net Profit Margin | 27.2% | 21.1% | 30.3% | 30.8% | 24.3% | 29.9% | 21.3% | 25.2% | 27.8% | 28.4% | 24.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Intuitive Surgical Inc dividends
Intuitive Surgical Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 3:1 on Oct 5, 2021.
Who owns Intuitive Surgical Inc
- Insiders 0.53%
- Institutions 90.86%
- Public & others 8.61%
- Shares outstanding 347M
- Free float 345M
Intuitive Surgical Inc company profile
- Company name
- Intuitive Surgical Inc
- Ticker
- IUI1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 17,021
- Fiscal year end
- December
- Address
- 1020 Kifer Road, Sunnyvale, CA, United States, 94086-5304
- Phone
- 408 523 2100
- Website
- intuitive.com
About Intuitive Surgical Inc
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Intuitive Surgical Inc management
10- Dr. Gary S. Guthart Ph.D.Executive Chair · born 1966
- Mr. David J. RosaCEO & Director · born 1968
- Mr. Jamie E. SamathExecutive VP, CFO & Enterprise Technology Leader · born 1971
- Mr. Henry L. CharltonSenior VP of Global Business Operations · born 1970
- Mr. Gary H. Loeb J.D.Executive VP and Chief Legal & Compliance Officer · born 1970
- Mr. Mark P. BrosiusEVP, Chief Manufacturing & Supply Chain Officer · born 1967
- Mr. Fredrik WidmanVP, Principal Accounting Officer & Corporate Controller
- Mr. Milind WagleChief Information Officer
- Mr. Daniel P. Connally C.F.A.VP & Head of Investor Relations
- Dr. Christopher R. Carlson Ph.D.Executive Vice President of Research, Corporate Development, Corporate Strategy & Intuitive Ventures